OutSee raises £2.5m in a seed round led by Ahren Innovation Capital to advance its genomics platform.
The oversubscribed financing was led by Ahren Innovation Capital and will support preclinical validation and platform development.
OutSee is a genomics and drug discovery company that uses predictive AI to identify therapeutic targets. The firm applies its Nomaly platform to precision medicine and target discovery.
OutSee has secured £2.5m in an oversubscribed seed funding round led by Ahren Innovation Capital. The capital will be directed towards advancing therapeutic targets through experimental validation and continuing research and development of the company proprietary Nomaly platform. Additional participants in the financing include Kadmos Capital, Panacea, Empirical Ventures, and 26 independent angel investors. Alongside the funding finalisation, OutSee has formed a strategic partnership with o2h discovery to progress its lead target candidate.
From the founder
"Partnering with the team at o2h discovery is a fantastic milestone for OutSee as we look ahead to commencing our first drug discovery programme and showcasing the potential of our Nomaly platform to revolutionise target discovery. The agreement is testament to the strength of our technology and, in combination with the closure of our oversubscribed seed funding round, kicks off a very exciting year. Thank you to our investors and supporters for their continued support, and the hard work and dedication of our team."
Julian Gough
CEO and Founder at OutSee
Use of funds
- 01Fund research and development
